title: Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes.
abstract: Data from a 20-week trial comparing insulin detemir and neutral protamine Hagedorn (NPH) insulin in insulin-naïve people with type 2 diabetes were analyzed using willingness-to-pay (WTP) data, a proxy for patient preference. The advantages of insulin detemir relative to NPH insulin with respect to a lower hypoglycemia rate and less weight gain were associated with a value of €27.87 per month.
authors.affiliation: Endocrine and Diabetes Centre, Karlstad Hospital, Karlstad, Sweden. johan.jendle@liv.se
authors.forename: J
authors.initials: J
authors.lastname: Jendle
authors.forename: M
authors.initials: M
authors.lastname: Ridderstråle
authors.forename: O
authors.initials: O
authors.lastname: Torfvitt
authors.forename: A
authors.initials: A
authors.lastname: Ericsson
authors.forename: S
authors.initials: S
authors.lastname: Larsen
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005382:Financing, Personal; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics* / Q000627:therapeutic use; D000069057:Insulin Detemir; D007336:Insulin, Isophane / Q000191:economics* / Q000627:therapeutic use; D049528:Insulin, Long-Acting / Q000191:economics* / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D057240:Patient Preference; D019727:Proxy; D013548:Sweden
chemical_list: D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; D000069057:Insulin Detemir; D007336:Insulin, Isophane